variants derived from the human small cell lung carcinoma line, NCI-H69, the mouse fibrosarcoma line, RIF-1 and the mouse mammary tumour cell line, EMT6. C219 produced positive staining in MDR variants of both human and mouse tumour cell lines. MRK 16 and JSB-1 however recognised P-glycoprotein only in the human MDR cell lines and not in the mouse MDR cells. 265/F4 appeared the most selective of the monoclonal antibodies used, producing positive staining of MDR variants derived from the RIF-1 line, but not of MDR variants derived from the EMT6 line. Total RNA was prepared from the mouse cell lines and, following reverse transcription, cDNA sequences were amplified by the polymerase chain reaction with primers specific for either the murine mdrla or the mdrlb genes. From this it was possible to show that only the mdrla gene is overexpressed in the resistant EMT6 lines that do not stain with 265/F4 whereas both mdrla and mdrlb are overexpressed in the positively staining resistant fibrosarcoma line, RIF/1.0. Low level expression of mdrlb was detected in the sensitive parent RIF-1 cells and increasing levels of expression correlated with increasing resistance in the lines, RIF/0.1, 0.2, 0.4 and 1.0. Expression of mdrla was found only in the more resistant fibrosarcoma cell lines. It seems that 265/F4 recognises only the mdrlb P-glycoprotein. Western blotting confirmed that this antibody detects a 170 kDa protein only in membranes derived from the resistant fibrosarcoma cells. 265/F4 may thus be used to distinguish between the murine P-glycoprotein isoforms so revealing differences between tumour cell lines in cellular localisation and in the time of appearance of mdrla and mdrlb P-glycoprotein following drug exposure.
Inherent and/or acquired patterns of cross-resistance to groups of cytotoxic drugs have proved major obstacles to the successful chemotherapy of cancer. One major mechanism of multidrug resistance involves the overexpression of P-glycoprotein on the cell surface (Juranka et al., 1989) . In an attempt to evaluate the importance of this putative drug efflux pump, a variety of monoclonal antibodies (MAbs) directed against the protein have been used on both normal and tumour tissue and on multidrug resistant (MDR) cell lines. These MAbs include C219, MRK 16 and JSB-1 all of which have been found appropriate for use on clinical material (Grogan et al., 1990) . Differences in staining patterns have however been observed with these antibodies (Van de Valk et al., 1990) . Although the basic P-glycoprotein structure is conserved across species, there are still structural differences between the P-glycoproteins of different species and of different tissues within species (Juranka et al., 1989) . In the mouse, there are three different genes coding for P-glycoproteins, alternatively known as mdrla, mdrlb and mdr2 (Hsu et al., 1989) or as mdr3, mdrl and mdr2 . In humans there are only two P-glycoproteinencoding genes, known as mdrl and mdr2 or as mdrl and mdr3 (Schinkel et al., 1991) . The selectivity of a particular antibody will thus depend on whether the epitope recognised is easily accessible, is in a region of the protein which is highly conserved between isoforms and whether it is unique to a specific P-glycoprotein.
Epitope mapping has helped in identifying more precisely the relevant sequences. C219 which was raised against solubilised membranes from both Chinese hamster ovary and human leukaemic MDR cells (Kartner et al., 1985) , is known to detect a cytoplasmic sequence six residues away from the consensus sequence of the B site of the proposed ATPbinding domain. This is a highly conserved amino acid sequence found in all P-glycoprotein isoforms characterised (Georges et al., 1990) . C219 therefore provides a fairly general probe for P-glycoproteins. It may however recognise sequences present on other proteins unrelated to P-glycoprotein (Thiebaut et al., 1989) . MRK 16, originally raised against intact adriamycin-resistant human myelogenous leukaemic cells (Hamada & Tsuruo, 1986) , recognises an external epitope on cells expressing the human mdrl gene but probably does not recognise P-glycoprotein from any other species. Its epitope encompasses at least two of six predicted extracellular peptide loops and so it has been suggested that the sequences involved which are separated by about 625 amino acids in the linear structure must be spatially situated in close proximity in the native protein (Georges et al., 1991) . There are also reports that sialation may mask detection of the epitope (Cumber et al., 1990) . Less is known about JSB-1. This antibody which was originally raised against a colchicine-selected mutant of a Chinese hamster ovary (CHO) cell line (Scheper et al., 1988) al., 1990) . A MAb, 265/F4, which was originally raised against resistant Chinese hamster ovary whole cells (Lathan et al., 1985) has also been used to stain human tissues. It detects a 170 kDa protein in CHO resistant cell membranes and also gives positive staining with MDR variants of mouse sarcoma and leukaemic cell lines (Volm et al., 1988a and b, 1989) . It has produced positive staining on resistant forms of human epidermoid lung cancer grown as xenographs (Volm et al., 1988a) and has stained cells in nine of 21 cases of human renal carcinoma (Bak et al., 1990) . In this study, essentially identical results were obtained with C219 used to stain parallel slides. However 265/F4 did not detect a 170 kDa protein in Western blots of cell membrane preparations from human resistant breast carcinoma cells (Lathan et al., 1985) .
The study described in this paper was undertaken to establish the appropriateness of C219, MRK 16, JSB-1 and 265/ F4 for detecting P-glycoprotein in certain of our drug resistant human and mouse tumour cell lines. As a result of the different staining patterns obtained, it became apparent that different P-glycoprotein isoforms were being expressed in the resistant mouse cells derived from different tumours. Preliminary results of some of this work have been reported pre-viously in abstract form (Barrand et al., 1990 .
Materials and methods

Cell lines
The human cell lines studied were the human small cell lung carcinoma line NC1-H69P and its resistant variants, H69/ LX4 and LX20 selected in adriamycin and H69/VR2 selected in vincristine. It has been shown previously that expression of human mdrl RNA is present in the resistant small cell lung lines (Reeve et al., 1989a) . These resistant lines were derived as described previously (Twentyman et al., 1986) and were maintained in RPMI 1640 medium supplemented with 10% foetal calf serum, penicillin and streptomycin (all Gibco Europe Ltd). The two mouse cell lines investigated were EMT6 originating from a mouse alveolar tumour nodule transplanted into a mammary fat pad (Rockwell et al., 1972) and RIF-1 obtained from a fibrosarcoma (Twentyman et al., 1980) . Cells were maintained in Eagle's minimum essential medium supplemented with either 20% new born calf serum or 10% foetal calf serum together with glutamine, penicillin and streptomycin. Resistant variants of EMT6 cells were derived by continuous growth of the parent (EMT6P) cell line in increasing concentrations of either adriamycin (ADM), vincristine (VCR) or colchicine (COL) and were maintained in the presence of the selecting drug at 0.2 Lg ml-' (CR0.2), 1 gIgml' (ARL.0, VR1.0) or 2figmlP' (CR2.0) (Reeve et al., 1989b) . Resistant variants of RIF cells were derived by adriamycin selection and were maintained in the presence of adriamycin at 0.1 ig ml-' (RIF 0.1), 0.2 ,tg ml-' (RIF 0.2), 0.4 ig ml1' (RIF 0.4) or 1.0 gLg ml' (RIF 1.0). Previous studies involving Northern blot analysis with probe pcDRI.3 for the mouse ADRl1 gene coding for Pglycoprotein revealed the presence of increased levels of mdr RNA of a size similar to that of human mdrl mRNA (Reeve et al., 1989a) in the resistant variants of both EMT6 and RIF cell lines (Twentyman et Table I .
Immunohistochemical detection of P-glycoprotein An alkaline phosphatase-antialkaline phosphatase (APAAP) method was used both for histochemical localisation and for whole cell ELISA assay. Cells harvested by trypsinisation followed by washing in phosphate buffered saline (PBS) were made into cytospins and air dried or absorbed to 96-well plates at 5 x I04 and 105 cells per well by overnight incuba- (Hsu et al., 1989 (Hsu et al., , 1990 ) and 2449-2432 in mdrlb otherwise termed mdrl (Gros et al., 1986b To obtain more quantitative analysis of the above immunohistochemical data, we performed whole cell ELISA assays on the mouse cell lines. These showed staining intensity with both C219 and with 265/F4 to increase in parallel with increasing resistance in the RIF cell lines (Table III) . C219 also produced strong staining with the resistant EMT6 cells, but there was not such a close correlation between resistance and absorbance in these EMT6 lines. Differences in cell size and therefore in membrane surface areas in EMT6 sublines derived in different drugs (the VCR-selected cells appear larger than the ADM-selected cells) will also influence the amount of P-glycoprotein measurable per cell.
Western blot analysis was conducted on membrane proteins prepared from both human and mouse resistant cell lines. When probed with JSB-1, a single major band at a position corresponding to a Mr of around 160-180 kDa was seen in membranes prepared only from human resistant cells, but not from sensitive parent human cells or resistant mouse cells. By contrast, when probed with 265/F4, a single 170 kDa band was seen in membranes prepared only from the resistant mouse fibrosarcoma RIF cell lines and no such band could be seen in membranes prepared from the resistant EMT6 cells (Figure 2a) or from resistant human cells. With C219, a 170 kDa band and two additional protein bands of about 85-95 kDa were evident in membranes prepared from the resistant cells of both the EMT6 and the RIF cell lines (Figure 2b ) and a single 170 kDa band in membranes from human resistant cells. However, when mouse resistant cell membranes were prepared in the presence of the protease inhibitors, aprotinin, leupeptin and pepstatin, rather than PMSF alone, only a single 170 kDa protein band was detected by C219 (Figure 2c ). It would appear therefore that the smaller bands represent degraded fragments of the larger 170 kDa protein.
In order to identify which genes encoding P-glycoprotein were being expressed in the mouse tumour cell lines, total RNA was prepared from both resistant and parent cells of EMT6 and RIF cell lines and following reverse transcription, cDNA sequences were amplified by the polymerase chain reaction using primers specific for either mdrla or mdrlb genes. Resolution of these amplified sequences on 2% agarose is shown in Figure 3 . With the mdrlb-specific forward primer, it was possible to distinguish an amplified DNA transcript corresponding in size to the expected 289 bp in material obtained from all the RIF cell lines, but not in that from the EMT6 cell lines. The band stained only weakly with ethidium bromide in the parent RIF line and most strongly in the most resistant RIF 1.0 line. With the mdrla-specific forward primer, a slightly larger amplified DNA sequence corresponding to the expected 446 bp was seen in material taken from all the resistant EMT6 cell lines. The band could also be distinguished, albeit weakly, in the parent EMT6. There was progressively increased expression of mdrlb in the resistant fibrosarcoma lines showing progressively increased levels of resistance, i.e. RIF/0.1, 0.2, 0.4 and 1.0. However Table II Immunoreactivity Values shown are the mean of data from 2-3 separate experiments. nd = not determined. expression of mdrla was evident only in the more resistant RIF cell lines (Figure 4) .
Southern blots were made from some of the gels containing the PCR products and were hybridised with the mouse-specific pcDR1.3 probe. Following washing to high stringency, autoradiographs revealed a major radioactive band corresponding in position to that of the 289bp sequence amplified with the mdrlb-specific primer. No radioactive band was evident at the position corresponding to that of the 446 bp sequence amplified with the mdrla-specific primer. This was not unexpected since the mdrla sequence amplified was from a region which shares little homology with the transcript of the mdrlb gene and the probe, pcDRl.3 was derived from a mouse cell line expressing only the mdrlb gene (Gros et al., 1986a (Thiebaut et al., 1989 (Volm et al., 1988a) and in frozen sections of human renal cell carcinoma where the distribution of staining paralleled that produced by C219 (Bak et al., 1990 ). Yet in our resistant human small cell lung carcinoma lines which stain strongly with other anti-P-glycoprotein antibodies, we were unable to detect any reactivity with 265/F4 either in cytospins or on Western blots. Similar negative findings have been reported with 265/F4 on resistant human breast carcinoma (Lathan et al., 1985) . There may be differences between P-glycoproteins expressed in different human tissues that will influence antibody recognition. For instance the disposition of the proteins within the membrane or post-translational modifications to the proteins may differ. Certainly the mdrlb P-glycoprotein expressed in mouse tissues appears to be glycosylated to different extents in uterine tissue and in MDR cell lines (Greenberger et al., 1989) . Surface modifications might well be significant for 265/F4 recognition since the antibody, raised originally against whole intact resistant cells, probably recognises an external epitope.
Despite the uncertainty surrounding the interpretation of the antibody recognition of the P-glycoprotein isoforms, it is clear from the data obtained by PCR that only mdrla is expressed in the mouse resistant mammary tumour cell lines whilst both mdrla and mdrlb are expressed in the resistant fibrosarcoma cell lines and that expression of mdrlb precedes that of mdrla during the acquisition of resistance. Expression of both mdrla and mdrlb within a single cell has been reported previously in other mouse drug resistant cell lines.
e.g. of the macrophage-like type (Hsu et al., 1989) . Here also the mdrlb gene alone was expressed in the lower resistance lines and higher resistance was associated with a switch to mdrla expression. The functional significance of these two different gene products is not yet clear but it has been suggested that the mdrla gene product may act as a more efficient pump to expel drug from the cells. Although both can confer multidrug resistance in transfection experiments, it has been shown that there are striking qualitative and quantitative differences in the drug resistance phenotype conveyed by these two genes (Devault & Gros, 1990) . In these particular experiments, cell clones expressing the mdrlb gene were more resistant to adriamycin and to colchicine than those showing an equivalent level of expression of the mdrla gene. In our cell lines, the mdrla protein appeared more susceptible than the mdrlb protein to degradation following disruption of cellular structure, smaller fragments being detectable on Western blots. However it has been reported that in intact cells, rates of degradation of these two gene products are similar . The different gene products have been detected in different amounts in different normal tissues in the mouse , very high levels of the mdrlb gene product being found in the uterus of the pregnant mouse where it may play an important role during gestation (Arceci et al., 1988; Greenberg et al., 1989) . The possibility is that they may therefore be involved with the transport of quite different endogenous substances. It is thought that each of these mdr genes is regulated in a tissuespecific manner. An understanding of the factors involved in this differential regulation may well therefore be important in designing cancer chemotherapy strategies .
